Tonghua Dongbao Pharmaceutical Co., Ltd. (SHA:600867)
8.60
+0.03 (0.35%)
Feb 3, 2026, 1:25 PM CST
SHA:600867 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,708 | 1,976 | 2,930 | 2,742 | 3,219 | 2,855 |
Other Revenue | 33.15 | 33.15 | 145.81 | 36.47 | 49.22 | 37.13 |
| 2,741 | 2,010 | 3,075 | 2,778 | 3,268 | 2,892 | |
Revenue Growth (YoY) | 12.74% | -34.66% | 10.69% | -14.98% | 12.99% | 4.14% |
Cost of Revenue | 790.58 | 547.46 | 621.05 | 628.13 | 586.99 | 582.86 |
Gross Profit | 1,951 | 1,462 | 2,454 | 2,150 | 2,681 | 2,309 |
Selling, General & Admin | 1,354 | 1,252 | 1,047 | 1,114 | 1,255 | 1,091 |
Research & Development | 140.65 | 99.3 | 104.96 | 146.71 | 166.86 | 106.93 |
Other Operating Expenses | 25.33 | 13.13 | 11.65 | 14.57 | 11.27 | -34.35 |
Operating Expenses | 1,513 | 1,349 | 1,184 | 1,268 | 1,435 | 1,165 |
Operating Income | 437.6 | 113.02 | 1,270 | 882.29 | 1,246 | 1,145 |
Interest Expense | -21.81 | -14.38 | -5.17 | -0.28 | - | -10.17 |
Interest & Investment Income | 1,211 | 130.82 | 103.61 | 942.66 | 304.32 | 43.64 |
Currency Exchange Gain (Loss) | 0.7 | 0.7 | 0.47 | 0 | 0.24 | -0.45 |
Other Non Operating Income (Expenses) | 251.31 | -1.14 | -1.65 | -0.88 | 0.33 | -7.38 |
EBT Excluding Unusual Items | 1,878 | 229.02 | 1,368 | 1,824 | 1,550 | 1,170 |
Gain (Loss) on Sale of Investments | - | 0.4 | 0.52 | 0.96 | -0.37 | 0.37 |
Gain (Loss) on Sale of Assets | -255.35 | -239.83 | -3.13 | -0.11 | -13.48 | -62.44 |
Asset Writedown | -106.24 | -80.68 | -7 | -1.74 | -11.53 | - |
Legal Settlements | -60.82 | -60.82 | - | - | - | - |
Other Unusual Items | -44.03 | 8.16 | 7.91 | 6.62 | 9.35 | - |
Pretax Income | 1,412 | -143.75 | 1,366 | 1,830 | 1,534 | 1,108 |
Income Tax Expense | 201.78 | -99.63 | 197.97 | 247.69 | 225.86 | 177.81 |
Earnings From Continuing Operations | 1,210 | -44.12 | 1,168 | 1,582 | 1,309 | 930.32 |
Minority Interest in Earnings | 15.69 | 1.4 | -0.09 | 0.06 | -0.34 | -0.41 |
Net Income | 1,226 | -42.72 | 1,168 | 1,582 | 1,308 | 929.92 |
Net Income to Common | 1,226 | -42.72 | 1,168 | 1,582 | 1,308 | 929.92 |
Net Income Growth | 259.17% | - | -26.17% | 20.92% | 40.69% | 14.63% |
Shares Outstanding (Basic) | 1,955 | 2,136 | 1,979 | 2,002 | 2,044 | 2,022 |
Shares Outstanding (Diluted) | 1,955 | 2,136 | 1,979 | 2,002 | 2,044 | 2,022 |
Shares Change (YoY) | -8.58% | 7.92% | -1.15% | -2.04% | 1.12% | -0.32% |
EPS (Basic) | 0.63 | -0.02 | 0.59 | 0.79 | 0.64 | 0.46 |
EPS (Diluted) | 0.63 | -0.02 | 0.59 | 0.79 | 0.64 | 0.46 |
EPS Growth | 292.86% | - | -25.32% | 23.44% | 39.13% | 15.00% |
Free Cash Flow | 213.89 | -108.99 | 513.4 | 370.21 | 579.62 | 712.69 |
Free Cash Flow Per Share | 0.11 | -0.05 | 0.26 | 0.18 | 0.28 | 0.35 |
Dividend Per Share | 0.250 | 0.250 | 0.250 | 0.500 | 0.300 | 0.210 |
Dividend Growth | - | - | -50.00% | 66.67% | 42.86% | 5.00% |
Gross Margin | 71.16% | 72.76% | 79.81% | 77.39% | 82.04% | 79.85% |
Operating Margin | 15.96% | 5.62% | 41.31% | 31.75% | 38.12% | 39.57% |
Profit Margin | 44.72% | -2.13% | 37.97% | 56.93% | 40.03% | 32.15% |
Free Cash Flow Margin | 7.80% | -5.42% | 16.69% | 13.32% | 17.74% | 24.64% |
EBITDA | 625.44 | 300.02 | 1,456 | 1,033 | 1,389 | 1,299 |
EBITDA Margin | 22.81% | 14.93% | 47.35% | 37.20% | 42.51% | 44.92% |
D&A For EBITDA | 187.84 | 187 | 185.87 | 151.17 | 143.65 | 154.54 |
EBIT | 437.6 | 113.02 | 1,270 | 882.29 | 1,246 | 1,145 |
EBIT Margin | 15.96% | 5.62% | 41.31% | 31.75% | 38.12% | 39.57% |
Effective Tax Rate | 14.29% | - | 14.49% | 13.54% | 14.72% | 16.05% |
Revenue as Reported | 2,741 | 2,010 | 3,075 | 2,778 | 3,268 | - |
Advertising Expenses | - | 93.24 | 63.59 | 46.79 | 143.61 | 120.46 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.